Patents Assigned to ID Biomedical Corporation
-
Patent number: 9433672Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: GrantFiled: April 28, 2014Date of Patent: September 6, 2016Assignee: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 9340586Abstract: The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: July 31, 2014Date of Patent: May 17, 2016Assignee: ID BIOMEDICAL CORPORATION OF QUEBECInventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Patent number: 8821895Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: October 24, 2012Date of Patent: September 2, 2014Assignee: ID Biomedical Corporation of QuebecInventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Publication number: 20140234374Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 8709447Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: GrantFiled: April 26, 2012Date of Patent: April 29, 2014Assignee: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 8580262Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: July 16, 2012Date of Patent: November 12, 2013Assignee: ID Biomedical Corporation of QuebecInventors: Bernard R. Brodeur, Clément Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Publication number: 20130136760Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: ApplicationFiled: October 24, 2012Publication date: May 30, 2013Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventor: ID Biomedical Corporation of Quebec
-
Publication number: 20130095498Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: July 16, 2012Publication date: April 18, 2013Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: Bernard R. Brodeur, Clément Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Publication number: 20120308596Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: June 7, 2012Publication date: December 6, 2012Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: Josee Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20120276140Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: April 26, 2012Publication date: November 1, 2012Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 8298551Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: September 28, 2009Date of Patent: October 30, 2012Assignee: ID Biomedical Corporation of QuebecInventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Patent number: 8226953Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: December 28, 2010Date of Patent: July 24, 2012Assignee: ID Biomedical Corporation of QuebecInventors: Bernard R. Brodeur, Clement Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Patent number: 8211437Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: December 9, 2009Date of Patent: July 3, 2012Assignee: ID Biomedical Corporation of QuebecInventors: Josée Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Patent number: 8173140Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: GrantFiled: October 22, 2004Date of Patent: May 8, 2012Assignee: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Publication number: 20110182923Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: December 28, 2010Publication date: July 28, 2011Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Clément Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Patent number: 7914794Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: January 13, 2003Date of Patent: March 29, 2011Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Clément Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Patent number: 7883706Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.Type: GrantFiled: January 12, 2009Date of Patent: February 8, 2011Assignee: ID Biomedical CorporationInventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault
-
Patent number: 7833717Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: November 16, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7811585Abstract: The present invention relates to antigens, more particularly an antigen of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: July 9, 2007Date of Patent: October 12, 2010Assignee: ID Biomedical CorporationInventors: Denis Martin, Josee Hamel, Bernard Brodeur, Stephane Rioux, Martine Boyer
-
Patent number: 7786286Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 16, 2006Date of Patent: August 31, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josée Hamel, Clement Rioux